|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Extracellular fragment of recombinant human c-erbB-3/HER-3 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunoprecipitation (IP)||2 µg/ml|
MA5-12867 targets HER-3 in FACS, IF, and IP applications and shows reactivity with Human samples.
The MA5-12867 immunogen is extracellular fragment of recombinant human c-erbB-3/HER-3 oncoprotein.
c-erbB-3/HER-3 is the third member of the type I family of growth factor receptors. It binds to ligands in the heregulin family. c-erbB-3 is over-expressed in a variety of tumors including breast, stomach, pancreas, and colon. Heregulin & EGF stimulate tyrosine phosphorylation of c-erbB-3 to different extents.
IP-MS enrichment of ERBB3 (LFQ intensity): ERBB3 was enriched 53-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB3 antibody (Part No. MA5-12867). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
MA5-12867 was used in flow cytometry to develop and characterize specific antibodies targeting EGFR family
|Horak E,Heitner T,Robinson MK,Simmons HH,Garrison J,Russeva M,Furmanova P,Lou J,Zhou Y,Yuan QA,Weiner LM,Adams GP,Marks JD||Cancer biotherapy & radiopharmaceuticals (20:603)||2005|
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
MA5-12867 was used in flow cytometry to compare ErbB2/beta-1 integrin/lipid raft interactions in cancer cells resistant and sensitive to Herceptin
|Mocanu MM,Fazekas Z,Petrás M,Nagy P,Sebestyén Z,Isola J,Tímár J,Park JW,Vereb G,Szöllosi J||Cancer letters (227:201)||2005|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
MA5-12867 was used in flow cytometry to study the role of HER-2/neu overexpression in increasing the viable hypoxic cell population within solid tumors
|Dragowska WH,Warburton C,Yapp DT,Minchinton AI,Hu Y,Waterhouse DN,Gelmon K,Skov K,Woo J,Masin D,Huxham LA,Kyle AH,Bally MB||Molecular cancer research : MCR (2:606)||2004|
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
MA5-12867 was used in flow cytometry to study the role of alpha6beta1 integrin in inducing proteasome-mediated cleavage of erbB2 in breast cancer cells
|Shimizu H,Seiki T,Asada M,Yoshimatsu K,Koyama N||Oncogene (22:831)||2003|
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
MA5-12867 was used in flow cytometry to study the role of the HER-2 receptor in modulating the response of ovarian cancer cells to doxorubicin, cisplatin and taxol
|Aigner A,Hsieh SS,Malerczyk C,Czubayko F||Toxicology (144:221)||2000|
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
MA5-12867 was used in flow cytometry to investigate the synergistic inhibitory effect of anti-HER2 antibody and anti-oestrogen on breast cancer cells
|Kunisue H,Kurebayashi J,Otsuki T,Tang CK,Kurosumi M,Yamamoto S,Tanaka K,Doihara H,Shimizu N,Sonoo H||British journal of cancer (82:46)||2000|
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
MA5-12867 was used in flow cytometry to study the role of ErbB-4 in the proliferation of estrogen receptor-positive breast cancer cells
|Tang CK,Concepcion XZ,Milan M,Gong X,Montgomery E,Lippman ME||Cancer research (59:5315)||1999|
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
MA5-12867 was used in immunoprecipitation to investigate the interaction between HER-2 and HPV-16 in human mammary epithelial cells during malignant transformation
|Woods Ignatoski KM,Dziubinski ML,Ammerman C,Ethier SP||Neoplasia (New York, N.Y.) (7:788)||2005|
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
MA5-12867 was used in immunohistochemistry to investigate the expression of heparin-binding epidermal growth factor-related factors and erbB receptors in normal and psoriatic keratinocytes
|Piepkorn M,Predd H,Underwood R,Cook P||Archives of dermatological research (295:93)||2003|
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
MA5-12867 was used in western blot to study the molecular mechanisms by which heregulin regulates the reorganization of the actin cytoskeleton and cell migration
|Adam L,Vadlamudi R,Kondapaka SB,Chernoff J,Mendelsohn J,Kumar R||The Journal of biological chemistry (273:28238)||1998|
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
MA5-12867 was used in immunocytochemistry to investigate the effect of ErbB-4 ribozymes on neuregulin-induced mitogenesis
|Tang CK,Goldstein DJ,Payne J,Czubayko F,Alimandi M,Wang LM,Pierce JH,Lippman ME||Cancer research (58:3415)||1998|
human epidermal growth factor receptor 3; proto-oncogene-like protein c-ErbB-3; receptor tyrosine-protein kinase erbB-3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
c-erbB-3; c-erbB3; ErbB-3; ERBB3; erbB3-S; HER3; LCCS2; MDA-BF-1; p180-ErbB3; p45-sErbB3; p85-sErbB3